

# A preliminary single-centre, randomised, comparative study of the Eakin wound dressing in the management of superficial/partial thickness wounds

<b>Submission date</b> 11/05/2005	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
<b>Registration date</b> 15/06/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 07/03/2017	<b>Condition category</b> Skin and Connective Tissue Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr Denis Harkin

**Contact details**  
Royal Group of Hospitals Trust  
Grosvenor Road  
Belfast  
United Kingdom  
BT12 6BA

## Additional identifiers

**Protocol serial number**  
TGE - W01

## Study information

**Scientific Title**

A preliminary single-centre, randomised, comparative study of the Eakin wound dressing in the management of superficial/partial thickness wounds

**Study objectives**

Eakin wound dressing is effective and safe for use on humans with superficial/partial thickness wounds.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Single-centre randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Wounds

**Interventions**

Eakin wound dressing will be trialled against a leading hydrocolloid wound dressing for a period of 5 weeks or until the wound has healed. Dressings will be changed every 4 days.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Eakin wound dressing

**Primary outcome(s)**

Confirmation of the clinical efficacy and safety of Eakin wound dressing when used in the treatment of superficial/partial thickness wounds. Wound is healed (or reduced in size) over a period of 5 weeks.

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

31/01/2006

# Eligibility

## Key inclusion criteria

All patients presenting superficial/partial thickness wounds which could or would normally be treated with a 'hydrocolloid' wound dressing, and who are not precluded by the exclusion criteria below, will be invited to participate in this clinical trial.

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

## Sex

All

## Key exclusion criteria

Patients will be excluded from the trial under the following circumstances:

1. Wound is >5 cm length or breadth
2. Wound is >0.5 cm depth
3. Wound involving muscle, tendon or bone
4. Wound infection is suspected
5. Where informed consent is withheld
6. Where patients are unable to give informed consent due to legal incompetence, unless informed consent is available from a responsible relative or guardian
7. Where, in the physician's opinion, inclusion in the trial is not advised

## Date of first enrolment

01/10/2005

## Date of final enrolment

31/01/2006

# Locations

## Countries of recruitment

United Kingdom

Northern Ireland

## Study participating centre

Royal Group of Hospitals Trust

Belfast

United Kingdom

BT12 6BA

# Sponsor information

## Organisation

TG Eakin Limited (UK)

## Funder(s)

### Funder type

Industry

### Funder Name

Full cost of trial will be funded by TG Eakin Limited (UK)

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration